AJTMH Transactions of the Royal Society of Tropical Medicine and Hygiene
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am. J. Trop. Med. Hyg., 77(6_Suppl), 2007, pp. 193-197
Copyright © 2007 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bosman, A.
Right arrow Articles by Mendis, K. N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bosman, A.
Right arrow Articles by Mendis, K. N.

A Major Transition in Malaria Treatment: The Adoption and Deployment of Artemisinin-Based Combination Therapies

Andrea Bosman* AND Kamini N. Mendis
World Health Organization, Geneva, Switzerland

Parasite resistance to conventional antimalarial medicines has led, in recent years, to a dramatic shift in malaria treatment. Sixty-seven countries with endemic Plasmodium falciparum malaria, 41 of them in Africa, have recently adopted the highly effective artemisinin-based combination therapies (ACTs). In 2005, 31.3 million ACT treatment courses were procured globally for public sector use, 25.5 million of them in Africa. However, in the 39 countries, and in particular the 21 African countries in which ACTs are being deployed, access to these medicines is still unacceptably low. After a period of market instability, the global manufacturing capacity for ACTs is now sufficient to meet the demand. However, increased and sustained financing will be necessary to extend the current levels of ACT coverage. Artemisinins as monotherapies are widely available in the private sector of 47 endemic countries, and their consumption will, if unabated, promote resistance to artemisinins and compromise the effectiveness of ACTs.


Received October 25, 2006. Accepted for publication November 7, 2006.

Acknowledgments: The authors thank Drs. Arata Kochi, Maryse Dugue, Peter Olumese, Pascal Ringwald, Wilson Were, and Sergio Spinaci, Francoise Mas, and Elise Pacquetet for ideas, helpful dialogue, and sharing information.

* Address correspondence to Andrea Bosman, Global Malaria Programme, World Health Organization, Av. Appia 20, 1211 Geneva, Switzerland. E-mail: bosmana{at}who.int

Authors’ addresses: Andrea Bosman, Global Malaria Programme, World Health Organization, Av. Appia 20, 1211 Geneva, Switzerland, Telephone.: 41-22-791-3860, Fax: 41-22-791-4824. Kamini N. Mendis, Global Malaria Programme, World Health Organization, Av. Appia 20, 1211 Geneva, Switzerland, Telephone: 41-22-791-3751, Fax: 41-22-791-4824.




This article has been cited by other articles:


Home page
Am J Trop Med HygHome page
J. G. Breman, M. S. Alilio, and N. J. White
Defining and Defeating the Intolerable Burden of Malaria III. Progress and Perspectives
Am J Trop Med Hyg, December 1, 2007; 77(6_Suppl): vi - xi.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society of Tropical Medicine and Hygiene.